Antibe starts Phase II trial of ATB-346 in healthy volunteers

Antibe Therapeutics Inc. (TSX-V:ATE; OTCQX:ATBPF) began a Phase II trial of pain candidate ATB-346 in healthy volunteers. The double-blind, placebo-controlled trial will evaluate once-daily 250 mg ATB-346 for 14 days vs. naproxen sodium in 240 patients undergoing upper gastrointestinal endoscopy prior to treatment. The company expects to complete the trial in early 2018...